About Us

NEX-I, First-In-Class Cancer Immunotherapy Development Company


Ground breaking immunotherapy,

A good companion
for the most valuable challenge

NEX-I isn't just another biotech firm — it's the future. We're pioneering a transformative shift in cancer immunotherapy, unveiling robust solutions – start with our 1st episode, ONCOKINE®. While conventional treatments often face resistance from evolving cancer cells, our groundbreaking platform identifies and counters this challenge. By understanding the mechanisms of refractory cancers and targeting ONCOKINE®, NEX-I sets a new standard. We're redefining the battle against cancer by actively inhibiting cancer cell growth and putting an end to metastasis. Experience the next era of cancer therapy with NEX-I.